Fig. 4From: Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargineLeft ventricular (LV) ejection fraction in type 2 diabetic patients at baseline and after 26-weeks of exenatide [dots; open dots (mean ± SD)] versus insulin glargine [squares; open squares (mean ± SD)]Back to article page